1 / 41

Whats new in Q: Qfeedback , QFracture, QCancer

Whats new in Q: Qfeedback , QFracture, QCancer. EMIS NUG conference September 2010 Warwick University. Julia Hippisley-Cox Sessional GP Epidemiologist Director QResearch Director ClinRisk Ltd. Acknowledgements. EMIS & EMIS Practices contributing data

cais
Download Presentation

Whats new in Q: Qfeedback , QFracture, QCancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Whats new in Q: Qfeedback, QFracture, QCancer EMIS NUG conference September 2010 Warwick University Julia Hippisley-Cox Sessional GP Epidemiologist Director QResearch Director ClinRisk Ltd

  2. Acknowledgements • EMIS & EMIS Practices contributing data • Many GPs & nurses for suggestions, piloting • University of Nottingham • Academic colleagues • ClinRisk Ltd (software) • THIN (validation data) • Oxford University – independent validation

  3. Overview • Update on QSurveillance • QFeedback • Update on QScores • QIntervention • QFracture • Qcancer • General discussion

  4. QSurveillance

  5. QSurveillance: Overview • Real time infectious diseases surveillance system • Vaccine uptake reporting system • History • 2004 - Pilot study on QResearch in 2004 • 2005 - Upgraded to online QFLU • 2006 – Separate Flu vaccine service • 2007 – Separate Pneumo vaccine service • 2007 – upgraded to QSurveillance Avon floods • Included prospective consent for data extraction in emergency • Key part of HPA and DH emergency response

  6. QSurveillance data extraction • Age/sex aggregated data • 100-150 indicators • Infectious diseases • Vaccine uptake – flu, pneumo, MMR • Daily, weekly, monthly, quarterly, annual reports • No patients can be identified • Counts < 5 suppressed

  7. QSurveillance Governance • JHC custodian & responsible to practices, profession, ethics etc • No patients identifiable • Counts < 5 suppressed • Process for new indicators: • Practice consent covers additional data extracted to support emergency response • consult with relevant agency re need, ethics and advisory board (including NUG)

  8. Governance Principles • Practice consent • Oversight board/review mechanism with NUG representation • Robust safeguards in place to protect patients and practices • Practices able to switch it on or off • Practice can access and benefit from data extracted

  9. QSurveillance: pandemic • Incredibly busy with flu pandemic • Daily reporting over 10 months • Unexpectedly high demand across NHS • Detailed coverage by media • Under resourced • Need to ensure its scalable, resilient, properly resourced. • Decision to industrialise it • Ensure practices can access and benefit from data

  10. Qfeedback System

  11. QScores

  12. Risk prediction tools - purpose • Population level • Risk stratification • Identification of rank ordered list of patients for recall or reassurance • Individual assessment • Who is most at risk of preventable disease? • Who is likely to benefit from interventions? • What is the balance of risks and benefits for my patient? • Enable informed consent and shared decisions

  13. Overview Qscores - disease outcomes • QRISK (CVD) • QDScore (diabetes) • QFracture • QKidney (CKD3b+) • Qcancer • Range of other significant outcomes • published • published • published • published • completed • In progress Disease outcomes Status

  14. Overview - risk/benefit interventions • Different approach needed • Assess baseline risk of outcomes • Then how they change with interventions • Use RCTs and meta analyses for benefits • Use database analyses for unintended effects • Starting with commonly used drugs e.g • Statins • Antidepressants • HRT • Warfarin • Antipsychotics • NSAIDS

  15. Vascular Risk Engine: Requirements • Identify patients at high risk of vascular disease • CVD • Diabetes • Stage 3b,4, 5 Kidney Disease • Assessment of individual’s risk profile • Risks and benefits of interventions • Weight loss • Smoking cessation • BP control • Statins

  16. QRISK2 www.qrisk.org • Risk of CVD & “Heart age” • Extensively reviewed and externally validated • Now included in • QOF • DH Vascular Guidance • NICE • Widespread use across NHS • Nearly all GP systems, many pharmacies, some hospitals, NHS Choices, Supermarkets, Occupational Health etc • Also free Open Source and Closed Software

  17. QDScore – risk of Type 2 diabeteswww.qdscore.org • Predicts risk of type 2 diabetes • Published in BMJ (2009) • Independent external validation by Oxford University • Needed as epidemic of diabetes & obesity • Evidence diabetes can be prevented • Evidence that earlier diagnoses associated with better prognosis.

  18. QKidney – risk of renal failurewww.qkidney.org • Set of algorithms • Identifies those at risk of • CKD3b+ • End Stage Renal Failure • Published BMC 2010 • So we can then • Identify high risk • Modify risk factors • Avoid nephrotoxic drugs • Monitor more closely • Prevent deterioration • Improve outcomes

  19. Risks and Benefits Statins(presented at NUG 2009) • Two recent papers: • Unintended effects statins (BMJ, 2010) • Individualising Risks & Benefits of Statins (Heart, 2010) • Conclusions: • New tools to quantify likely benefit from statins • New tools to identify patients who might get rare adverse effects eg myopathy for closer monitoring

  20. Why integrated tool CVD, diabetes, CKD? • Many of the risk factors over overlap • Many of the interventions overlap • But different patients have different risk profiles • Smoking biggest impact on CVD risk • Obesity has biggest impact on diabetes risk • Blood pressure biggest impact on CKD risk • Help set individual priorities • Development of personalised plans and achievable target

  21. Primary prevention CVD:(slide from NICE website) • Offer information about: • absolute risk of vascular disease • absolute benefits/harms of an • intervention • Information should: • present individualised risk/benefit • scenarios • present absolute risk of events • numerically • use appropriate diagrams and text

  22. Qinterventionwww.qintervention.org

  23. QFracture

  24. QFracture: Background • Osteoporosis major cause preventablemorbidity & mortality. • 2 million women affected in E&W • 180,000 osteoporosis fractures each year • 30% women over 50 years will get vertebral fracture • 20% hip fracture patients die within 6/12 • 50% hip fracture patients lose the ability to live independently • 1.8 billion is cost of annual social and hospital care

  25. Patients with Symptomatic Vertebral Fractures • Scane et al, Osteoporosis Int 1994; 4: 89-92.

  26. QFracture: challenge • Effective interventions exist to reduce fracture risk • Challenge is better identification of high risk patients likely to benefit • Avoiding over treatment in those unlikley to benefit or who may be harmed • Some guidelines recommend BMD but high cost and low specificity • Other guidelines recommend using 10 year risk of fracture

  27. QFracture: development • Cohort study using patient level QResearch database • Similar methodology to QRISK • Published in BMJ 2009 • Algorithm includes established risk factors • Undertook validation against FRAX • Developed risk calculator which can • - identify high risk patients for assessment • - show risk of fracture to patients

  28. QFracture vs FRAX comparison • Primary care • Works better in EMIS • Open Source • No funding • Includes extra risk factors eg • Falls • CVD • Type 2 diabetes • Asthma • Antidepressants • Detail smoking/Alcohol • HRT • Selected cohorts • Over-predicts in EMIS • Not published • Industry sponsored • NOGG guidance QFracture FRAX

  29. Clinical example • 64 year old women • Heavy smoker • Non drinker • BMI 20.6 • Asthma • On steroids • Rheumatoid • H/O falls

  30. Effect of interventions to reduce fracture risk in our example 64 year old women with a 20% fracture risk(note: her QRISK CVD risk is 18%)

  31. Balancing risks vs benefits • Need to quantify risks of interventions • Few large long term safety studies • Bisphosphonates may increase risk of • Oesophageal cancer • Atrial fibrillation • Osteonecrosis of jaw • Atypical fracture • ? Other outcomes • Key thing for my patient is • Baseline risk of fracture • Likely benefit of intervention • risk of adverse effects of intervention • What is the overall risk/benefit ratio?

  32. QCancer

  33. QCancer scores • Tools to predict risk of range of common cancers • Risk stratification: • Identify those who need regular screening • Identify those who need ad hoc assessment • Patient communication • Background risk with family history – may be reassuring • Risk of cancer with “alarm” symptoms • Risks of cancer with smoking as decision aid for smoking cessation • Current • Ex smoker • Non smoker

  34. QCancer Scores • Breast cancer • Prostate • Colorectal • Oesophageal • Renal/bladder • Lung • Ovary • Uterus • Breast lump • Prostatism • Rectal bleeding • Dysphagia • Haematuria • Haemoptysis • Abdo pain/distension • Post menopausal bleeding Cancers Alarm symptoms

  35. See www.qresearch.org for • Information about QResearch database • Academic papers • Technical & statistical documents • Open source software • Patient information • Clinician information • Power points presentations • Information on how to contribute to the database (or email julia.hippisley-cox@nottingham.ac.uk )

  36. Discussion • Questions • Comments • Suggestions • Feedback

More Related